JGC
ADMS

J. Goldman & Co’s Adamas Pharmaceuticals ADMS Stock Holding History

J. Goldman & Co’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-97,480
Closed -$422K – 593
2020
Q4 		$422K Buy
+97,480
New +$417K 0.02% 289
2017
Q1 		– Sell
-71,500
Closed -$1.21M – 439
2016
Q4 		$1.21M Sell
71,500
-48,367
-40% -$748K 0.08% 209
2016
Q3 		$1.97M Sell
119,867
-49,133
-29% -$747K 0.11% 184
2016
Q2 		$2.56M Buy
+169,000
New +$2.79M 0.13% 159

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return

J. Goldman & Co's ADMS Position: Q1 2021 in Review

J. Goldman & Co sold out of Adamas Pharmaceuticals (ADMS) in Q1 2021, closing a stake of 97,480 shares — an estimated $422K sold.

J. Goldman & Co first reported a position in ADMS in Q2 2016 and held it in 4 quarters. The position peaked at $2.56M in Q2 2016. 73 funds tracked by Wall St. Rank hold ADMS as of Q1 2021.

  • J. Goldman & Co reported no remaining Adamas Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • J. Goldman & Co sold 97,480 Adamas Pharmaceuticals shares in Q1 2021, an estimated $422K.
  • J. Goldman & Co first reported a position in Adamas Pharmaceuticals in Q2 2016 and held it in 4 quarters.
  • J. Goldman & Co's Adamas Pharmaceuticals position peaked at $2.56M in Q2 2016.
  • 73 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2021.

Based on J. Goldman & Co's 13F filing for Q1 2021, filed 17 May 2021.